Opendata, web and dolomites

AptaCheck

Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

15    biochips    industry    aptamer    turnover    quality    scalable    later    reader    flu    detecting    infectious    optimisation    manufacturing    lab    2024    easily    diagnostics    aptachek    samples    direct    mover    drawbacks    industrial    infections    preventing    clinical    aptacheck    action    departments    biosensor    disposable    8m    human    consolidated    lower    observation    instability    market    adequately    strategic    platform    portability    minutes    groundbreaking    communication    accuracy    time    2020    house    parallel    point    skills    microbiological    qr    jobs    clinically    scanner    fast    versatile    cutting    revenues    detection    drug    isolated    elisa    antibody    special    semi    approvals    automated    simplicity    cumulative    wireless    poc    electronic    handling    eventual    linked    downstream    identifications    supply    accurate    gastroenteritis    enter    care    hospitals    financing    obligatory    data    pcr    transfer    beats    74    pathogens    600    secure    complete    clinics    immediately    display    first    outbreaks    equipped    3bn    patients    approved    chip    advantage    overcome    diagnosis    wifi    markets    chain    edge   

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator
SOLSTEN DIAGNOSTICS AS 

Organization address
address: HEDEAGER 40
city: AARHUS N
postcode: 8200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://solsten-diag.com
 Total cost 2˙254˙187 €
 EC max contribution 1˙577˙931 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLSTEN DIAGNOSTICS AS DK (AARHUS N) coordinator 1˙577˙931.00

Map

 Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

 Deliverables

List of deliverables.
Portfolio of communication material Other 2020-02-18 15:41:04

Take a look to the deliverables list in detail:  detailed list of AptaCheck deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

NAS (2018)

Nexilis augmentation system

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More